The Gazette

CND Life Sciences is Granted FDA Breakthrough Device Designation for Its Skin Biopsy-Based Syn-One Test®

SCOTTSDALE, Ariz., Oct. 7, 2025 /PRNewswire/ — CND Life Sciences, Inc. (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker ...
Seeking Alpha

CND Life Sciences Announces Publication of Study Demonstrating Clinical Utility of the Syn-One Test® as an Important Aid in the Diagnosis and Treatment of Neurodegenerative ...

Findings from retrospective chart review of patients with suspected Parkinson's disease and related disorders show the use of skin biopsy for detection of abnormal synuclein in cutaneous nerves ...
KXAN

CND Life Sciences' Syn-One® Biomarker Services Used for Novel Parkinson's Disease Endpoint in Phase 2 Drug Trial

As Part of an Exploratory Outcome, ABLi Therapeutics Used CND's Syn-One Biomarker Services to Quantify and Visualize a Decrease in Phosphorylated Alpha-Synuclein in Cutaneous Nerves of Patients in a ...
KTLA

CND Life Sciences' Syn-One Test® Detects Alpha-Synuclein in Skin Biopsies of Patients with REM Sleep Behavior Disorder

CND Life Sciences announces baseline results from Syn-Sleep Study to be presented at SLEEP 2025. iRBD is a sleep disorder that causes affected individuals to act out their dreams, often with violent ...